logo-loader

BriaCell having discussions with pharma companies on combination therapies

Published: 10:08 12 Feb 2019 EST

BriaCell Therapeutics (OTCQB: BCTXF) CEO Bill Williams sat down with Proactive Investors at the BIO CEO & Investor Conference in New York.

BriaCell is currently conducting a Phase I/IIa clinical trial of Bria-IMT, its lead candidate, in a combination study with pembrolizuma. BriaCell is also developing Bria-OTS, a personalized immunotherapy to treat advanced breast cancer.

BenevolentAI advances novel ulcerative colitis treatment through Phase 1a trial

BenevolentAI (OTC:BAIVF) chief scientific officer Dr Anne Phelan joins Proactive's Stephen Gunnion with positive safety data from the Phase 1a, first-in-human, clinical study of BEN-8744 in healthy volunteers. Phelan explained that BEN-8744 is a potent, selective PD10 inhibitor, uniquely...

2 hours, 6 minutes ago